PRIMARY STUDY
Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia.
Key Findings: Researchers present clinical and preclinical evidence suggesting CBD and other cannabinoids have therapeutic effects in Parkinson's disease and L-DOPA-induced dyskinesia.
Type of Study: Meta-analysis
Study Result: Positive
Cannabinoids Studied: Cannabidiol (CBD), Cannabinoid (unspecified), Synthetic Cannabinoid (unspecified)
Phytocannabinoid Source: Not Applicable
Form of Administration: Not Applicable
Receptors Studied: TRPs, PPARs
Ligands Studied: Anti-inflammatory cytokines, Pro-inflammatory cytokines
Study Location(s): Brazil
Year of Pub: 2019
Link to study